Selected Medicines in Development for Mental Illness

Anxiety (Social Phobia) – Anxiety disorders affect more than 40 million adults in the U.S., with about 15 million of those suffering from acute social phobia, according to the National Institute of Mental Health.  A potential medicine in development is part of a new class of psychotropic pherines.  The drug, which has a unique mechanism of action, is administered in an intranasal spray and acts with rapid-onset on peripheral receptors from nasal chemosensory neurons that act on the hypothalamic-limbic system in the brain, which is thought to be the primary center of emotion

Medicines in Development for Mental Illnesses - 2012 Report

PhRMA Statement on Patent Reform - 2011

Washington, D.C. (June 23, 2011) — The Pharmaceutical Research and Manufacturers of America Deputy Vice President Karl Uhlendorf today released the following statement regarding patent reform:

Cumulative Gains Are Building Blocks to Incredible Progress in War Against Cancer

Washington, D.C. (June 12, 2012) — Following Food and Drug Administration (FDA) approval of a new cancer medicine, it often takes years of additional research to fully understand the value of the medicine to patients, according to "Recognizing Value in Oncology Innovation," a new paper released by the Boston Healthcare Associates (BHA).

Recognizing Value in Oncology Innovation Report

Recognizing Value In Oncology Innovation Executive Summary

Nearly 1,000 Medicines in Development to Help Patients in Their Fight Against Cancer

PhRMA Urges President Obama to Secure an Ambitious Trans-Pacific Partnership Agreement

Washington, D.C. (May 8, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

“PhRMA joins with a large group of U.S trade associations urging President Obama to complete his vision for a strong, ambitious Trans-Pacific Partnership Agreement (TPP) which would further economic growth by strengthening American trade with the Asia-Pacific region.

PhRMA Statement on Special 301 Report

Washington, D.C. (May 2, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) released the following statement today on the Special 301 Report issued by the United States Trade Representative (USTR).

Medicines in Development for Vaccines

Washington, D.C. (April 20, 2012)— America’s biopharmaceutical research companies are developing nearly 300 vaccines for the prevention and treatment of a wide variety of diseases, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The vaccines – all either currently tested in clinical trials or under review by the Food and Drug Administration – include 170 for infectious diseases, 102 for cancers and eight for neurological disorders.


Subscribe to RSS - Innovation